Status:

WITHDRAWN

Phase Analysis and Obstructive CAD on Rubidium PET

Lead Sponsor:

Emory University

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18-90 years

Phase:

PHASE2

Brief Summary

Rubidium myocardial perfusion PET is an imaging test used to diagnose patients with abnormal blood flow to the heart secondary to narrowing of the heart vessels. Phase analysis is a computer method t...

Eligibility Criteria

Inclusion

  • Male or female patients
  • referred for myocardial perfusion imaging for suspected obstructive CAD
  • 18 years of age or older.

Exclusion

  • Contraindications to regadenoson radionuclide imaging including severe reactive airway disease, unstable crescendo angina, high grade AV block, caffeine within 24 hours
  • Documented prior myocardial infarction
  • Severe claustrophobia
  • Patients who may be pregnant.

Key Trial Info

Start Date :

October 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2014

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01840696

Start Date

October 1 2013

End Date

May 1 2014

Last Update

June 2 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emory University Hospital

Atlanta, Georgia, United States, 30322

Phase Analysis and Obstructive CAD on Rubidium PET | DecenTrialz